Castle Biosciences
Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic
The company's DecisionDx-SCC is meant to predict risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.
The company said it is developing a new genomic test to predict therapeutic response in patients with inflammatory skin conditions.
Castle Biosciences Q1 Revenues Up 31 Percent
The company said it delivered 11 percent fewer DecisionDx-Melanoma test results year over year, but that the total number of all tests delivered rose 4 percent.
Castle Biosciences Acquires Myriad Genetics' MyPath Melanoma Test, Lab for $32.5M
The sale, part of Myriad's planned strategic refocusing of its business, will allow Castle to bolster its pipeline of tests for dermatologic cancers.
Castle Biosciences Q4 Revenues Down 2 Percent
The skin cancer diagnostics company said it delivered 5 percent fewer DecisionDx-Melanoma test results in Q4 2020 than in the previous year's fourth quarter.
Nov 9, 2020
Castle Biosciences Q3 Revenues Up 3 Percent
Aug 10, 2020
Castle Biosciences Q2 Revenues Up 18 Percent
Jun 25, 2020
Castle Biosciences Prices $74M Public Offering
May 11, 2020
Castle Biosciences Doubles Q1 Revenues
Nov 11, 2019